eftilagimod alfa + carboplatin plus paclitaxel + cisplatin or carboplatin + pemetrexed + pembrolizumab (KEYTRUDA®)
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Conditions
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Trial Timeline
Mar 21, 2025 → Sep 1, 2029
NCT ID
NCT06726265About eftilagimod alfa + carboplatin plus paclitaxel + cisplatin or carboplatin + pemetrexed + pembrolizumab (KEYTRUDA®)
eftilagimod alfa + carboplatin plus paclitaxel + cisplatin or carboplatin + pemetrexed + pembrolizumab (KEYTRUDA®) is a phase 3 stage product being developed by Merck for Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC). The current trial status is active. This product is registered under clinical trial identifier NCT06726265. Target conditions include Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC).
What happened to similar drugs?
0 of 1 similar drugs in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06726265 | Phase 3 | Active |
Competing Products
20 competing products in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)